Ionis, Recordati License Zilganersen
Analysis based on 6 articles · First reported Jun 25, 2026 · Last updated Jun 26, 2026
The market is positively impacted by the potential for a new treatment for Alexander disease, a rare and fatal neurological disorder. Ionis Pharmaceuticals' stock is expected to rise due to the upfront payment, milestone payments, and royalties from the agreement, as well as the potential for its first independent neurology launch in the U.S. Recordati's rare disease portfolio is strengthened, which could also positively impact its market valuation.
Ionis Pharmaceuticals has entered into a license agreement with Recordati, granting Recordati exclusive rights to develop and commercialize zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), in all countries outside the U.S. Ionis Pharmaceuticals will retain sole commercial responsibility for zilganersen in the U.S. and will continue to lead global development. Under the terms, Ionis Pharmaceuticals will receive an upfront payment of $30 million, additional milestone payments, and tiered royalties up to the mid-20% range on annual net sales. Zilganersen is currently under review by the United States — Food and Drug Administration with a PDUFA action date of September 22, 2026, and has received multiple designations including Breakthrough Therapy and Orphan Drug from both the United States — Food and Drug Administration and the European Union — European Medicines Agency. This partnership aims to bring a much-needed treatment option to patients with Alexander disease globally.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard